Digital Therapeutic Shows Promise for Schizophrenia’s Negative Symptoms

An investigational prescription digital therapeutic demonstrated in a phase 3 trial that it could reduce the negative symptoms of schizophrenia.

In the trial, CT-155, which is being developed by Boehringer Ingelheim and Click Therapeutics, is being used as an adjunct to standard-of-care antipsychotic therapy in people diagnosed and living with schizophrenia experiencing negative symptoms.

An estimated 24 million worldwide have schizophrenia, according to the World Health Organization . People with schizophrenia have persistent delusions and hallucinations. Up to 60% of people with schizophrenia have negative symptoms, which include an inability to feel pleasure, having a flat affect or other speech problems and often lacking motivation.

Current medications, however, are not approved